A Novel Treatment Path
Steba Biotech’s technology consists of a minimally-invasive treatment that combines a photosensitive drug with activation by a non-thermal light delivery system. Utilizing a low-energy laser light channeled through optical fibers, this treatment provides a new approach to localized tumors, with the potential to treat various sites in the body.
This therapeutic approach enables targeted ablation of solid tumors locally and minimizes the risk of side effects by preserving the surrounding healthy tissues and organs. It thereby enables treatment of sometimes inoperable tumors and optimizes quality of life of patients.
After an initial focus on prostate cancer, our partnership with the Weizmann Institute and the Memorial Sloan Kettering Cancer Center has allowed us to explore multiple additional indications our technology can be applied to.
ImPACT (Immune Photo Activated Cancer Therapy) is a novel, minimally invasive, and targeted treatment option, which is approved in Europe, Israel, and Mexico for the treatment of patients with early stage prostate cancer and under investigation for other localized tumors (urothelial, esophageal, lung, pancreatic). It is a drug-device combination that features a light activated drug and a light delivery system. The drug is administered intravenously and is activated locally with light fibers that deliver low-energy, non-thermal laser light with accuracy. Upon activation, the drug rapidly triggers the constriction of the blood supply in the illuminated area only, resulting in targeted tumor necrosis that activates anti-tumor immunity which enhances cancer cells eradication.